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ABSTRACT
The net beneﬁt (i.e., beneﬁts minus costs) of sustained-
release (SR) bupropion for smoking cessation from an
employer’s perspective has previously been evaluated in
clinical trials including frequent, in-person behavioral
counseling and manufacturer recommended dosing but
not in actual practice settings and lower dosing.
Objectives: The objective of this research was to deter-
mine the return on investment (ROI) and internal rate of
return (IRR) from an employer’s perspective of two dos-
ing schedules of bupropion SR in combination with
behavioral interventions of minimal intensity (tailored
mailings, TM) or moderate intensity (proactive telephone
calls, PTC) in an actual practice setting.
Methods: An open-label, randomized trial with 1-year
follow-up was conducted in a large health system (Group
Health Cooperative) based in Seattle, WA. Participants
included 1524 adult smokers interested in quitting smok-
ing. Participants were randomly assigned to receive
150 mg of bupropion SR daily and PTC (n = 382),
150 mg of bupropion SR daily and TM (n = 381), 300 mg
of bupropion SR daily and PTC (n = 383) or 300 mg of
bupropion SR daily and TM (n = 378). Sufﬁcient medica-
tions for 8 weeks of dosing were provided to patients. The
primary outcome measure of the ﬁeld trial was self-
reported point-prevalence 7-day nonsmoking status at
12 months, and the primary outcome measures of the
economic analysis were employer net beneﬁt, employer
ROI, and the ROI-associated IRR using 2002 dollars.
Results: Using  net  beneﬁt,  the  300-mg/PTC  and  the
150-mg/PTC treatments were approximately equally
preferred. Using ROI or IRR, both the 150-mg/TM and
150-mg/PTC treatments were about equally preferred,
with IRR values of 31.7% and 31.4%, respectively. Under
a pessimistic scenario regarding effectiveness and costs,
150 mg/PTC became more cost-effective than 150 mg/
TM, and employer IRR for 150 mg/PTC was 13%. Under
an optimistic scenario IRR exceeded 45% for all
treatments.
Conclusions: These results suggest that employers can
receive competitive returns on investment from sponsor-
ing smoking cessation programs, that 150 mg of bupro-
pion doses yield better returns than 300-mg doses, and
that PTC treatments should be preferred to TM if smok-
ing cessation rates in the targeted employee population
are lower than those in the study population.
Keywords: bupropion SR, cost-effectiveness, health-care
setting, internal rate of return, net beneﬁt, return on
investment, smoking cessation, treatment outcome.
Introduction
Several placebo-controlled trials of bupropion sus-
tained-release (SR) for smoking cessation have dem-
onstrated it to be efﬁcacious in promoting smoking
cessation [1–5]. However, the published trials of
bupropion SR included intensive in-person behav-
ioral counseling during and/or following treatment,
much more contact than individuals receiving a
bupropion SR prescription from their doctor will
typically receive. Success rates for bupropion SR in
combination with truly minimal counseling as
deﬁned by recent guidelines [6,7] have not been
reported. Therefore, recommendations based on
results from these studies [8,9] are of unknown
applicability to settings outside of a clinical efﬁcacy
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trial. In addition, there has only been a single eco-
nomic evaluation of the cost-beneﬁt of sponsoring a
smoking cessation program using bupropion from
an employer’s perspective [10], and that evaluation
was based on a study that used a dose of 300 mg
per day, despite the lack of statistical difference
between 12-month outcomes at 300 mg per day
and the less costly dose of 150 mg per day. Finally,
that economic evaluation used a net beneﬁt
approach for the evaluation of a 300-mg daily dose
rather than ﬁnancial measures such as cost-beneﬁt,
return on investment (ROI), or internal rate of
return (IRR) that are more applicable to business
decision-making. The current study provides a basis
for making an informed decision on the beneﬁt to
employers of smoking cessation programs delivered
in a primary care-oriented health-care setting, with
minimal to moderate behavioral intervention, using
dose levels at 150 mg and 300 mg per day, and eval-
uated using ﬁnancial measures applicable to busi-
ness decision-making.
In the only published cost-beneﬁt analysis of
bupropion for smoking cessation from an
employer’s perspective, Nielsen and Fiore [10]
compared smoking cessation treatments using pla-
cebo, the nicotine transdermal patch (NTP),
300 mg of bupropion SR, and a combination of
300 mg of bupropion SR and NTP, with corre-
sponding 12-month nonsmoking rates of 15.6%,
16.4%, 30.3%, and 35.5%, respectively. Drug
costs were based on the average wholesale price
for bupropion SR and the NTP, administered per
labeling ($163.49 and $245.24, respectively, in
1998). All treatment arms received the same coun-
seling, which included nine supportive telephone
calls, nine weekly individual smoking cessation
counseling sessions, and relapse prevention coun-
seling during four follow-up clinic visits. Despite
these intensive behavioral interventions, Nielsen
and Fiore conducted their cost analysis as if indi-
viduals received only a single brief counseling ses-
sion with a health-care provider. Nielsen and Fiore
estimated the midpoint cost for behavioral treat-
ment based on a single brief counseling session
with a health-care provider to be $37.50, even
though more intensive counseling was provided.
Including costs for “brief medical counseling,” the
cost per enrollee for placebo, NTP, bupropion, and
bupropion/NTP groups were estimated to be
$37.50, $283, $201, and $446, respectively. Divid-
ing these values by the 12-month nonsmoker rate
yields the cost per 12-month nonsmoker of $240,
$1724, $663, and $1257, respectively. The yearly
beneﬁt to an employer from smoking cessation
was estimated as $1654 per 12-month nonsmoker
(in 1998 dollars, based on the work of Kristein
[11]).  Multiplying  this  value  by  the  12-month
nonsmoking rates, the beneﬁt per enrollee for the
treatments was $258, $271, $501, and $587,
respectively. Thus, the 1-year net beneﬁt (beneﬁts
less costs) per enrollee for these four treatment
combinations can be estimated as $220, –$12,
$300, and $141, respectively. Nielsen and Fiore
therefore concluded that the optimal smoking ces-
sation program from an employer’s perspective
was the treatment consisting of brief counseling
and 300 mg of bupropion.
Although  Nielsen  and  Fiore  used  net  beneﬁt
as  the primary evaluation criteria, in business it is
common to evaluate alternative investment options
using ROI [12] and IRR [13]. ROI is how many
dollars the employer gains (after expenses) per
dollar expended, and is related to the cost-beneﬁt
(CB) ratio. IRR is the rate of returns, when
applied to costs and allowed to compound over
time, is equal to beneﬁts. Relevant formulas are as
follows:
ROI = [(NPV of beneﬁts) - (NPV of costs)]/
(NPV of costs) (1)
CB = (NPV of beneﬁts)/(NPV of costs)
= ROI + 1 (2)
IRR = [(NPV of beneﬁts)/(NPV of costs)]1/n - 1
= (ROI + 1)1/n - 1 (3)
Investment choices made on the basis of ROI,
IRR, and CB will be identical. However, net beneﬁt
will sometimes yield different conclusions than
either ROI or IRR. Using the costs and beneﬁts
stated earlier, the 1-year ROI for the four treatments
considered by Nielsen and Fiore are 588%, -4%,
149%, and 32%, respectively. This suggests that the
optimal strategy for the employer would be to
encourage employees to quit with brief counseling
and placebo, in contrast to the conclusion reached
by Nielsen and Fiore that the optimal investment
was brief counseling and 300 mg of bupropion.
Methods
Study Design
The present study analyzed the economic returns of
an effective trial of bupropion SR’s effectiveness in
an HMO setting. The trial, conducted at Group
Health Cooperative (GHC) in Seattle, WA, con-
sisted of four groups deﬁned by crossing two bup-
ropion regimens (150 mg and 300 mg/day, each
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administered for up to 8 weeks) with two different
counseling approaches. The more intensive coun-
seling program was the Free & Clear program,
which involves proactive telephone calls (PTC) with
a tobacco cessation specialist. The less intensive
program was a modiﬁed version of the Zyban®
Advantage Plan (ZAP™) program, which relies pri-
marily on tailored mailings (TM).
Participants, all members of GHC, were enrolled
over a 13-month period, between April 1998 and
May 1999. GHC is a nonproﬁt consumer-governed
health-care system headquartered in Seattle, WA; it
serves approximately 600,000 residents of Wash-
ington State. The study was advertised in various
publications mailed to GHC members and in bro-
chures distributed to GHC clinics. Primary care
physicians were informed of the study and were
asked to refer eligible patients. A total of 2979
smokers interested in the study underwent a
detailed telephone screening and 1909 of them were
determined to be eligible. Inclusion/exclusion crite-
ria were modeled after the two previously con-
ducted bupropion SR efﬁcacy trials [1,2] and
focused predominantly on conditions, including use
of medications, that may lower seizure threshold.
The pretreatment questionnaire and informed con-
sent were obtained from 1524 smokers who were
then randomized into one of the four treatment
groups. Of the 385 smokers who did not end up in
the ﬁnal sample, 323 (84%) did not return their
enrollment materials or subsequently refused partic-
ipation, 23 (6%) were found not to have proper
coverage, and the remaining 10% either reported
exclusion criteria after screening, or were excluded
by their personal physician. The ﬁnal sample of
1524 averaged 45.1 years of age, was 57.4%
female, 89.7% white, and smoked an average of
23.2 cigarettes per day prior to treatment. Com-
pared to the sample characteristics from previous
efﬁcacy trials of bupropion SR [1,2], the present
sample was similar in most respects except for a
somewhat higher percentage of individuals with
high school or less education [14].
Participants randomized to the less intensive
behavioral counseling were automatically enrolled
in ZAP. Selected data from the pretreatment ques-
tionnaire, along with data from four brief progress
questionnaires sent after the target quit date, were
used to personalize the ZAP intervention materials.
Patients also received a ZAP evaluation question-
naire and a 5- to 10-minute scripted call from a
ZAP smoking cessation specialist on the day after
their quit date. ZAP participants could return the
progress questionnaires in provided postage paid
envelopes or they could complete the questionnaires
using ZAP’s automated telephone system. Par-
ticipants also had access to a 24-hour automated
toll-free Zyban question and answer and support
line.
Participants randomized to receive higher inten-
sity counseling were enrolled in the Free & Clear
(FC) phone program [15,16], which is based on
cessation strategies recommended by the United
States Public Health Service (USPHS) tobacco treat-
ment guideline [6,7]. FC included mailing of self-
help materials plus support materials for family and
friends. In addition to an in-depth phone assessment
and counseling intervention and four brief pre-
scheduled follow-up calls, participants had access to
a toll-free quit line for a full year. Counselors pro-
vided individualized counseling for participants on
motivation, quitting, avoiding the return to smok-
ing, and “recycling” (returning to nonsmoking fol-
lowing an episode of smoking within the follow-up
period). The program version used in this trial was
1 year long with outgoing call activity concentrated
in the ﬁrst 6 months. Patients could continue in
either behavioral intervention even if they had
stopped taking medication prematurely or had
resumed smoking.
Self-assessed point-prevalence smoking status of
these participants was determined via survey at
12 months asking about smoking behavior in the
last  7 days.  We  assigned  the  status  of  smoker  to
the 14.1% of participants who did not respond to
the survey. (The survey response rates for the four
treatment groups were 84% for 150 mg/PTC, 88%
for 150 mg/TM, 82% for 300 mg/PTC, and 88%
for 300 mg/PTC and the association between survey
response status and treatment group was not signif-
icant, P < 0.06. For comparisons of dose regimens
within behavioral treatments, the differences in
response rates were negligible. The lower response
rates for the PTC versus the TM groups suggest that
the smoking cessation rates for PTC may be under-
estimated relative to that of TM). To determine the
effectiveness of bupropion and counseling in actual
practice, participants were not blinded to dose.
Reported nonsmoking was not conﬁrmed by bio-
chemical analyzes. Details concerning trial methods
and outcomes are presented elsewhere [14,17].
Cost Estimates
The costs for the telephonic and tailored mail pro-
grams were estimated from the various components
of those programs that would be used on an ongo-
ing basis and excludes those components of the trial
that served only research purposes (i.e., primarily
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an extensive background survey and follow-up sur-
veys at 3 and 12 months). Costs for the various
behavioral intervention components were estimated
based on the amount and type of personnel time
involved, local wage rates and overhead beneﬁts,
facilities costs, time spent on indirect tasks related
to an ongoing smoking cessation behavioral inter-
vention program (departmental meetings, quality
control activities, etc.), telephone costs, manage-
ment costs, printing, and postage. Cost estimates
for behavioral components were based on the actual
use of resources for historical groups that had sim-
ilar smoking cessation rates to the groups in this
study.
Drug costs were estimated based on contract
pricing, pharmacy dispensing costs, and allocable
pharmacy overhead. All medications were sent to
the participants prior to their anticipated quit dates.
Because unused medications were not returned nor
were pill counting caps used, medication costs were
based on the cost of ﬁlling the prescriptions rather
than on the basis of the number of pills consumed.
Slightly, more patients did discontinue bupropion in
the higher-dose groups than in the lower-dose
groups because of adverse reactions. The discontin-
uation rate for this reason was 25.9% in the 150-
mg dose groups versus 31.1% in the 300-mg dose
groups.
Costs were not included for advertising, training
or informing physicians or other medical staff, staff
hiring and training, program development, materi-
als development, or IT infrastructure investment
because these would be primarily nonrecurring
costs.
Because almost all costs were incurred within the
ﬁrst few months of the smoking cessation program,
costs were not discounted. This results in a negligi-
ble underestimation of ROI and IRR of about 0.5%
to 1.0%.
Cost-Effectiveness Calculations
The outcome measure of the 7-day point-prevalence
nonsmoking at 12 months was reduced by 11% to
account for the background proportion of smokers
who would be expected to be abstinent in any 7-day
time period [18], and therefore represents the
increase in the 7-day point-prevalence nonsmoking
attributable to treatment.
Estimates of employer’s beneﬁts of smoking ces-
sation were derived from Warner et al. [19] who
modeled employees entering a smoking cessation
program on a continuing basis. By the ﬁfth year of
the program the cumulative beneﬁts to the employer
per successful quitter, including employees who had
been abstinent anywhere from 0 to 5 years, were
estimated at $2327 in 1995 dollars, discounted by
3.5%, which we have increased using the general
rate of inﬂation to $2745 in mid-2002 dollars. As a
percentage breakdown of this total, beneﬁts were
24.8% from reduced medical expenditures 18.9%
from reduced absenteeism (i.e., a reduction of 3.9
illness days for men and 2.1 illness days for women,
prorated by years after cessation), and 52.9% from
on-the-job productivity gains. On-the-job smoking-
related productivity loss was estimated as 1% of
salary (i.e., 5 minutes per 8-hour day). Even in non-
smoking facilities, where smoking is supposed to be
restricted to authorized break times, such losses are
possible [20]. Nielsen and Fiore [10] used 8 minutes
per day as an estimate of productivity losses and
states that this value is “still a likely underesti-
mate.” The estimates by Warner et al. are lower on
a per annum basis than those obtained in previous
studies that include the costs of medical care, absen-
teeism, accidents, and lost work time [21] and that
range from highs of $10,408 [22] and $8172 [23],
to a low of $1483 [11] after adjustment to 1994
dollars.
We have not modiﬁed the estimate of productiv-
ity losses to reﬂect potential productivity gains from
smoking because the evidence for such gains is
inconclusive. While exposure to nicotine in labora-
tory-based studies involving the careful administra-
tion of known concentrations of nicotine enhances
several cognitive functions (e.g., attention, memory,
learning, and executive control [24–27]), the impact
of smoking, per se, on cognition is much less clear.
For example, a recent laboratory-based study of
smoking one or two cigarettes daily had no observ-
able impact on memory, calculation, or mental asso-
ciation [28]. In addition, nicotine deprivation, such
as could occur during the workday prior to smoking
breaks, can lead to impairment in attention and
cognitive abilities [29,30]. Larger studies in a work-
place environment reveal that relative to former
smokers, smokers show reduced levels on objective
measures of productivity [31].
We have adjusted Warner et al.’s estimate to
account for the varying amount of time that the
quitters were in the program. Because smokers
enrolled in the smoking cessation program consid-
ered by Warner et al. in different years, by the ﬁfth
year of the program the average quitter considered
by Warner et al. had been abstinent for only 3 years.
We increased productivity beneﬁts, which are
attributable to additional time working while not
engaging in smoking related activities, by a factor of
5/3 = 1.67 to estimate the productivity beneﬁts that
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would have occurred if all quitters had been absti-
nent for a full 5 years. Other beneﬁts would have
increased by at least a factor of 1.67 if all quitters
had been abstinent for a full 5 years because those
beneﬁts tend to increase with time since cessation.
However, because Warner did not provide the pro-
ration schedule for those other beneﬁts, we also
conservatively multiplied other beneﬁts by 1.67.
This increased the beneﬁt per 5-year quitter to
$4575.
We also adjusted Warner et al.’s estimate for
those who relapsed. Previous research cited in Fis-
cella and Franks [32] and Stapleton et al. [33] esti-
mate a 35% to 40% lifetime probability of relapse
from smoking cessation after 1 year of abstinence,
so lifetime nonsmoking rates were calculated
assuming a 37% relapse rate for 12-month abstain-
ers. Over a 2-year period we assumed that approx-
imately 20% of 12-month quitters would relapse
and over a 5-year period approximately 30% of 12-
month quitters would relapse. Counting those who
relapsed, 12-month quitters account for approxi-
mately 82.4% of the number of abstinent years that
would have occurred in a 5-year time period with-
out relapse. Therefore, we multiplied our estimate
of $4575 by 82.4% to yield a 5-year beneﬁt of
$3744 per 12-month quitter.
Sensitivity Analysis
We examined the sensitivity of our results to varia-
tion in parameter values by developing two scenar-
ios that modiﬁed parameters in such a way that ROI
is minimize or maximize, denoted as the pessimistic
and optimistic scenarios, as shown in Table 1. Opti-
mistic and pessimistic values for smoking cessation
rates were based on the upper and lower bounds of
95% conﬁdence intervals. For other parameters, the
optimistic and pessimistic values were selected as a
result of consideration of values reported in the lit-
erature or used in other sensitivity studies, or were
based on our opinions of a range of plausible val-
ues. In addition, we examined the sensitivity of our
results holding all parameters except for the smok-
ing cessation rates at their baseline values and recal-
culating the ROI and IRR measures with the
smoking cessation rates at the upper and lower
bounds of their 95% conﬁdence intervals.
Results
The information necessary to calculate the
employer net beneﬁt, the ROI, and the IRR is
shown in Table 2. The net beneﬁt to the employer
from these interventions ranged from $343 to $569,
with TM having considerably lower net beneﬁts
than PTC. Thus, on the basis of net beneﬁt, PTC
would be preferred, with essentially no preference
between 150-mg and 300-mg doses. The 5-year
ROI for any of the four treatments was excellent,
ranging from a high of 297% (equivalent to a 32%
annual IRR) for the 150-mg/TM group to a low of
166% for 300 mg/PTC (IRR = 22%). Compared to
the approximate inﬂation-adjusted 10% annual
rate of return for stocks over the past 75 years [34],
any of these treatments would be a good invest-
ment. However, the 150-mg treatments had the
highest IRR and the 300-mg treatments had the
lowest.
If we had based our employer analysis on the
work of Kristein [11], as did Nielsen and Fiore [10],
rather than on the work of Warner et al. [19], we
would have obtained higher IRRs, because the sin-
gle year employer beneﬁt from a 12-month quitter
in mid-2002 dollars would be $1825. In this case
the IRRs for 150 mg/PTC, 300 mg/PTC, 150 mg/
TM and 300 mg/TM would have been 91%, 43%,
Table 1 Parameters used in sensitivity analysis
Parameter
Economic scenario
Baseline Pessimistic Optimistic
12-month nonsmoking rates (%)
Motivated smokers on placebo 11.0 15.4 7.7
150 mg/PTC 31.4 26.7 36.1
300 mg/PTC 33.2 28.5 37.9
150 mg/TM 23.6 19.3 27.9
300 mg/TM 25.7 21.3 30.1
Cost of  PTC ($) 104 130 78
Cost of  TM ($) 28 35 21
Cost of  150 mg bupropion SR ($) 91 114 68
Cost of  300 mg bupropion SR ($) 179 224 134
Relapse rate for 12-month quitters (%) 37.0 46.0 26.0
Discount rate for life years and QALYs (%) 3.0 5.0 0.0
Employer’s 5-year beneﬁts per 12-month abstainer ($) 3745 2884 5768
Abbreviations: PTC, proactive telephone counseling; QALYs, quality adjusted life-years; TM, tailored mailing.
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93%, and 30%, respectively, all of which exceed
customary rates of return and would therefore be
good investment candidates.
The results from applying the optimistic and
pessimistic scenarios are shown in Table 3. For the
pessimistic scenario, employer’s 5-year ROI ranges
from a high of 84% for 150 mg/PTC (equivalent
to a 13% IRR) to a low of 12% for 300 mg/TM
(equivalent to a 2.2% IRR). Thus, even under this
scenario, the risk to employers from subsidizing
150-mg/PTC treatments would appear to be very
small. The IRR for 150 mg/TM is 9.1%, which
indicates that even though it has a better IRR
than 150 mg/PTC under the baseline scenario, the
rate of return under the pessimistic scenario is
lower.
Under the optimistic scenario, the cost for each
additional 12-month nonsmoker (above the
expected rate in a placebo group) ranges from a low
of $560 for 150 mg/TM to a high of $861 for
Table 2 Employer’s ROI using baseline estimates
Bupropion-counseling combined therapy
150 mg/PTC
n = 382
300 mg/PTC
n = 383
150 mg/TM
n = 381
300 mg/TM
n = 378
12-month cessation rate (%) 31.4 33.2 23.6 25.7
Incremental 12-month nonsmoking rate* (95% CI) 20.4
(16.4–24.4)
22.2
(18.0–26.4)
12.6
(9.3–15.9)
14.7
(11.1–18.3)
Cost of  interventions per enrollee ($)
Behavioral intervention 104 104 28 28
Drug costs 91 179 91 179
Total cost per enrollee 195 283 119 207
Cost per additional nonsmoker at 12 months ($) 956 1275 944 1408
5-year beneﬁt to employer per 12-month nonsmoker ($) 3745 3745 3745 3745
5-year beneﬁt to employer per enrollee ($) 764 832 472 550
Net beneﬁt to employer per enrollee ($) 569 548 353 343
Total ROI over 5 years (%) 292 194 297 166
IRR per year (%) 31.4 24.1 31.7 21.6
*Calculated by subtracting the 12-month nonsmoking rate for placebo (11%) from the 12-month nonsmoking rate for that treatment group.
Abbreviations: IRR, internal rate of  return; PTC, proactive telephone counseling; ROI, return on investment; TM, tailored mailing.
Table 3  Employer’s ROI using pessimistic and optimistic scenarios
Bupropion-counseling combined therapy
150 mg/PTC 300 mg/PTC 150 mg/TM 300 mg/TM
Pessimistic scenario
Incremental 12-month nonsmoking rate (%)* 16.0 17.8 8.2 10.3
Lifetime nonsmoking rate (%) 8.6 9.6 4.4 5.6
Cost of  interventions per enrollee ($)
Behavioral intervention 130 130 35 35
Bupropion costs 114 224 114 224
Total cost per enrollee 244 354 149 259
Cost per additional nonsmoker at 12 months ($) 1525 1989 1817 2515
5-year beneﬁts to employer per 12-month nonsmoker ($) 2809 2809 2809 2809
5-year beneﬁt to employer per enrollee ($) 449 500 230 289
Net beneﬁts to employer per enrollee ($) 205 146 81 30
Total ROI over 5 years (%) 84 41 55 12
IRR per year (%) 13.0 7.1 9.1 2.2
Optimistic scenario
Incremental 12-month nonsmoking rate (%)* 23.7 25.5 15.9 18.0
Lifetime nonsmoking rate (%) 17.5 18.9 11.8 13.3
Cost of  interventions per enrollee ($)
Behavioral intervention 78 78 21 21
Drug costs 68 134 68 134
Total cost per enrollee 146 212 89 155
Cost per additional abstainer at 12 months ($) 616 831 560 861
5-year beneﬁts to employer per 12-month nonsmoker ($) 5618 5618 5618 5618
5-year beneﬁts to employer per enrollee ($) 1331 1433 893 1011
Net beneﬁt to employer per enrollee ($) 1185 1221 804 856
Total ROI over 5 years (%) 812 576 904 552
IRR per year (%) 55.6 46.5 58.6 45.5
*Calculated by subtracting the 12-month nonsmoking rate for placebo from the 12-month nonsmoking rate for that treatment group.
Abbreviations: PTC, proactive telephone calls; TM, tailored mail.
Return on Investment of Bupropion SR and Counseling 541
300 mg/TM. Employer’s 5-year ROI ranged from a
high of 904% for 150 mg/TM (IRR = 58.6%) to a
“low” of 552% for 300 mg/TM (IRR = 45.5%).
Table 4 shows the effect of holding all parame-
ters constant except the smoking cessation rate at
baseline, and varying the smoking cessation rates
over their baseline, pessimistic and optimistic val-
ues. As shown, if one of these treatments is at its
optimistic smoking cessation rate and the remaining
treatments are at their pessimistic smoking cessa-
tion rates, then the treatment at the optimistic rate
will have the highest ROI. However, the 231% ROI
of the 300-mg/TM treatment at the optimistic
smoking cessation rate enjoys such a small advan-
tage over the 214% ROI of the 150 mg/PTC at its
pessimistic smoking cessation rate that for all prac-
tical purposes the 300-mg/TM treatment should not
be considered as a treatment option. The 249%
ROI of the 300-mg/PTC treatment at its optimistic
smoking cessation rate holds a very modest advan-
tage over the 214% ROI for the 150-mg/PTC treat-
ment at its pessimistic smoking cessation rate and
lags behind the 292% ROI of the 150-mg/PTC
treatments at its observed smoking cessation rate.
Therefore, it is unlikely that the payoff from the
300-mg/PTC treatment would actually exceed that
of the 150-mg/PTC treatment, and this argues for
nonselection of the 300-mg/PTC treatment. Finally,
the 150-mg/PTC and the 150-mg/TM treatments
have similar ROIs under observed, pessimistic, and
optimistic scenarios, with the advantage shifting
slightly depending on scenario. Neither of these two
treatments shows a great advantage over the other.
Conclusions
Our ﬁnding of substantial employer’s beneﬁts from
sponsoring smoking cessation interventions is con-
sistent with other studies [10,11,19,21–23]. How-
ever, unlike other studies, we explicitly considered
ROI (beneﬁts minus costs as a proportion of costs)
and IRR (the rate of return that, when applied to
costs and allowed to compound over time, is equal
to beneﬁts) in addition to net beneﬁt (beneﬁts minus
costs). The ROI measure is among the most com-
monly used measurement of ﬁnancial return in busi-
ness, where the net beneﬁts of an investment must
be judged relative to its costs, because alternative
investments with greater returns may be available.
Furthermore, when ROI rather than net beneﬁt is
used as the decision criteria, the optimal treatment
regime can change. In our study, the 300-mg/PTC
treatment had a nearly optimal net beneﬁt even
though it was the most expensive treatment. When
ROI was used as the basis for decision-making, the
optimal treatment was the 150-mg/TM treatment,
the least expensive one. Similarly, using Nielsen and
Fiore’s [10] cost estimates for the Jorenby data [2],
the optimal treatment varies depending on whether
net beneﬁt or ROI is used. The use of net beneﬁt for
decision-making  could  lead  to  a  misspeciﬁcation
of the underlying business model for employer-
sponsored smoking cessation efforts. This, in turn,
could lead to a long-term rejection of other treat-
ments that, if evaluated from the perspective of
ROI, have outstanding underlying business models.
We recommend that employers be provided both
with net beneﬁt and either ROI, IRR, or cost-beneﬁt
measures, depending on employer preferences for
ﬁnancial measures.
In our study, ROI was quite favorable for both of
the 150-mg dose treatments using baseline assump-
tions (averaging 31.5%), and was slightly greater
than the assumed market returns of 10% for the
150-mg/PTC intervention (13%) even under a pes-
simistic scenario. Health-care providers might
further increase employer ROI by modifying the
treatment to provide an initial prescription of
bupropion limited to 3 weeks with a subsequent
prescription dependent on abstinence at that time
[18]. In addition, when bupropion’s patent expires,
medication costs can be expected to decline. Using
current prices, however, this study concludes that
following the manufacturer’s recommendation of
using a 300-mg dose will result in a less cost-
effective  program  for  employers  than  using  a
150-mg dose.
The ﬁndings of this study should be interpreted
with caution because of the limitations inherent in
the methodology and assumptions related to: 1)
Table 4 Employer’s 5-year ROI using baseline, pessimistic, and optimistic values for smoking cessation rates and holding other
parameters at their baseline values
Bupropion-counseling combined therapy
150 mg/PTC 300 mg/PTC 150 mg/TM 300 mg/TM
Using pessimistic smoking cessation rate (%) 214 139 192 101
Using baseline smoking cessation rate (%) 292 194 297 166
Using optimistic smoking cessation rate (%) 369 249 401 231
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demographic characteristics of the study population
(which  may  differ  from  employee  demographics);
2) lack of a placebo group or bioveriﬁcation of
reported nonsmoking; 3) coding of participants
who were missing 12-month outcomes as smokers;
and 4) absence of consideration of the costs of
adverse effects of bupropion. An additional limita-
tion is that for some employers, Warner’s calcula-
tion of employer’s beneﬁt may not be applicable; an
example of this is when employees can smoke on
the job without reducing their productivity.
The study sample used in these analyses was
predominantly Caucasian and middle class, and
consisted of volunteers who knew that they would
receive bupropion. Smoking cessation rates
achieved in this population may not be reﬂective of
smoking cessation rates in the general population.
The study also was not blinded, and did not include
a placebo group. For the ﬁeld trial, nonrespondents
were coded as smokers, which may have slightly
decreased the 12-month cessation rates and the esti-
mates of cost-effectiveness. There were not any seri-
ous adverse effects reported in this study, although
an increase in minor adverse effects, such as insom-
nia, was  seen  with  higher  levels  of  bupropion.
Had costs for such effects been included, cost-
effectiveness would have been lower. Given the
transience of these minor adverse effects, and the
availability of written material and counselors to
explain these effects, associated medical expenses
were probably minimal.
The absence of biochemical conﬁrmation of non-
smoking may have resulted in an overestimation of
the true abstinence rate. Comparison of nonsmok-
ing rates obtained in the present trial with those
reported from the two previous trials of bupropion
SR that included biochemical veriﬁcation [1,2] sug-
gest a consistency across the three studies. Previous
analyses suggest that the rate of underreporting of
smoking in a ﬁeld trial of this type may be minimal
[35–38].
In summary: 1) the use of ROI and IRR results
in a more compelling business case for employer-
sponsored smoking cessation treatments than the
use of net beneﬁts, because the latter does not
measure the beneﬁt obtained per dollar invested,
although net beneﬁt can be useful in justifying to
an employer that the total “proﬁt” from an invest-
ment would be large enough to warrant its fur-
ther consideration using ROI or IRR; 2) the use of
150-mg daily dose of bupropion results in a higher
ROI than 300 mg; and 3) employer sponsorship of
a smoking cessation program using 150 mg of
bupropion and either PTC or TM can result in a
higher ROI than many other investment options.
One of the barriers to more widespread corporate
sponsorship of disease prevention efforts such as
smoking cessation could well be the lack of trans-
lation of employer’s health costs and beneﬁts into
terms the business community uses on a daily
basis to make decisions. We would encourage oth-
ers in the public health community involved in
economic analyses of disease prevention programs
to calculate ROI and IRR values as a matter of
routine practice. In so doing, corporate managers
will be able to make informed decisions about the
inclusion of workforce disease prevention invest-
ments as viable investment alternatives for their
portfolios.
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